UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.851-859

2015

Volltextzugriff (PDF)

Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study

Clinical lymphoma, myeloma and leukemia, 2015-07, Vol.15 (7), p.443-449

2015

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies

Journal of clinical oncology, 2000-01, Vol.18 (1), p.178-186

2000

Volltextzugriff (PDF)

CLO19-037: Reducing the Duration, Incidence and Severity of Mucosal Injury Due to Cancer Radiation therapy (RT); Positive Randomized Phase 2b Trial Results With GC4419 (Avasopasem Manganese), a Small Molecule Superoxide (SO) Dismutase (SOD) Mimetic

Journal of the National Comprehensive Cancer Network, 2019-03, Vol.17 (3.5), p.CLO19-037

2019

Volltextzugriff (PDF)

Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2531-2531

2015

Volltextzugriff (PDF)

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2532-2532

2014

Volltextzugriff (PDF)

A Phase I Study of Raltitrexed, an Antifolate Thymidylate Synthase Inhibitor, in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 1999-09, Vol.5 (9), p.2381-2391

1999

Volltextzugriff (PDF)

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7029-7029

2014

Volltextzugriff (PDF)

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

Clinical lymphoma, myeloma and leukemia, 2015-03, Vol.15 (7), p.443-449

2015

Volltextzugriff (PDF)

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

Journal of clinical oncology, 1998-09, Vol.16 (9), p.3007-3015

1998

Volltextzugriff (PDF)

Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia

Journal of clinical oncology, 1998-07, Vol.16 (7), p.2313-2320

1998

Volltextzugriff (PDF)

Neurotoxicity of purine analogs: a review

Journal of clinical oncology, 1994-10, Vol.12 (10), p.2216-2228

1994

Volltextzugriff (PDF)

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2001-10, Vol.48 (4), p.269-274

2001

Volltextzugriff (PDF)

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction

Journal of clinical oncology, 1997-05, Vol.15 (5), p.2125-2134

1997

Volltextzugriff (PDF)

Clinical use of thymidine as a rescue agent from methotrexate toxicity

Investigational new drugs, 1991-08, Vol.9 (3), p.281-290

1991

Volltextzugriff (PDF)

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma

Journal of clinical oncology, 1991-10, Vol.9 (10), p.1811-1820

1991

Volltextzugriff (PDF)

A pilot study of γ-1b-interferon in combination with fluorouracil, leucovorin, and α-2a-interferon

Clinical cancer research, 1997-07, Vol.3 (7), p.1125-1134

1997

Volltextzugriff (PDF)

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia

Leukemia & lymphoma, 1991, Vol.5 (S1), p.119-122

1991

Volltextzugriff (PDF)

Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Nature communications, 2018-04, Vol.9 (1), p.1340-9, Article 1340

2018

Volltextzugriff (PDF)

Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Nature communications, 2019-01, Vol.10 (1), p.419-419, Article 419

2019

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Female
(11)
Male
(11)
Adult
(10)
Middle Aged
(10)
Science & Technology
(10)
Aged
(9)
Biological And Medical Sciences
(9)
Life Sciences & Biomedicine
(9)
Medical Sciences
(9)
Oncology
(9)
Pharmacology. Drug Treatments
(9)
Antineoplastic Agents
(6)
Antineoplastic Agents - Adverse Effects
(6)
Dose-Response Relationship, Drug
(5)
Administration, Oral
(4)
Chemotherapy
(4)
Neoplasms - Drug Therapy
(4)
Aged, 80 And Over
(3)
Antineoplastic Agents - Administration & Dosage
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study

Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies

CLO19-037: Reducing the Duration, Incidence and Severity of Mucosal Injury Due to Cancer Radiation therapy (RT); Positive Randomized Phase 2b Trial Results With GC4419 (Avasopasem Manganese), a Small Molecule Superoxide (SO) Dismutase (SOD) Mimetic

Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

A Phase I Study of Raltitrexed, an Antifolate Thymidylate Synthase Inhibitor, in Adult Patients with Advanced Solid Tumors

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia

Neurotoxicity of purine analogs: a review

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction

Clinical use of thymidine as a rescue agent from methotrexate toxicity

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma

A pilot study of γ-1b-interferon in combination with fluorouracil, leucovorin, and α-2a-interferon

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia

Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Suchergebnisse filtern